Vaccine Therapy Plus QS21 in Treating Women With Breast Cancer Who Have No Evidence of Disease
|ClinicalTrials.gov Identifier: NCT00003357|
Recruitment Status : Completed
First Posted : August 16, 2004
Last Update Posted : December 13, 2012
RATIONALE: Vaccines made from GM2-KLH and given with QS21 may make the body build an immune response to and kill tumor cells.
PURPOSE: Phase I trial to study the effectiveness of GM2-KLH vaccine plus QS21 in treating patients with breast cancer who have no evidence of disease.
|Condition or disease||Intervention/treatment||Phase|
|Breast Cancer||Biological: GM2-KLH vaccine Biological: QS21||Phase 1|
OBJECTIVES: I. Determine whether immunization with GM2-KLH vaccine plus the immunological adjuvant QS21 induces an antibody response against GM2 and cells expressing GM2 in disease free patients at high risk for recurrence of breast cancer.
OUTLINE: GM2-KLH vaccine plus QS21 is administered subcutaneously to sites on the upper arm and upper leg at weekly intervals for 4 weeks. Two additional vaccines are administered at weeks 12 and 24. Patients are followed every 3 months after the sixth vaccination.
PROJECTED ACCRUAL: A total of 9 patients will be accrued for this study within 1 year.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||9 participants|
|Official Title:||Vaccination of High Risk Breast Cancer Patients Lacking Identifiable Disease With GM2-KLH Conjugate Plus the Immunological Adjuvant QS21|
|Study Start Date :||January 1998|
|Actual Primary Completion Date :||November 2001|
|Actual Study Completion Date :||November 2001|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003357
|United States, New York|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10021|
|Study Chair:||Teresa Ann Gilewski, MD||Memorial Sloan Kettering Cancer Center|